by Philippa Clark, Director of Business Development, One Nucleus

I recently attended a women‑led science event, and it’s one of those occasions that stays with you for reasons you don’t fully expect. It wasn’t a single presentation or statistic that caught my attention, but a theme that kept resurfacing throughout the day and gradually shifted how I was thinking about the whole topic.

For a long time, conversations about women’s health have understandably focused on what’s missing: the gaps in diagnosis, the lack of funding, and the treatments that don’t reflect the realities of women’s biology. Those gaps are real and frustrating, and they absolutely deserve attention, but someone raised a point that made me pause and look at the issue from a different angle: perhaps the problem isn’t only that women’s health has been underserved but that women’s biology itself represents one of the most underexplored opportunities in science.

Once that idea settled, it became hard not to spot examples everywhere!

Pregnancy is an obvious starting point, and from an immunological perspective, it is pretty remarkable. The body manages to tolerate a genetically distinct human growing inside it, something that, in any other context, would be considered an anomaly worth intense scientific scrutiny. If we understood that tolerance more deeply, it could reshape how we think about autoimmune disease, transplantation or even cancer immunology. Yet pregnancy research is often treated as a specialist niche rather than a source of broader biological insight.

Breastfeeding offers another great example. During lactation, bone density temporarily decreases as calcium is redirected into milk production and then the body rebuilds that bone once breastfeeding ends. A natural cycle of bone loss and regeneration happening in real time. If we understood that mechanism properly, imagine what it could mean for osteoporosis and other bone‑related conditions.

Even conditions like Polycystic Ovary Syndrome, which are usually discussed in the context of fertility, are now revealing deeper links to metabolism, insulin signalling and long‑term disease risk. A condition affecting millions of women may also be pointing us toward new metabolic pathways that could benefit far more people than we currently recognise.

Despite all of this, many of these questions still sit at the edges of mainstream research. There are historical reasons for that: women were routinely excluded from clinical trials for decades because hormonal cycles were considered too complex and pregnancy research came with understandable ethical caution. Over time, those decisions shaped the scientific agenda, leaving entire areas of human biology surprisingly underexplored.

Women’s bodies move through biological states that simply don’t occur elsewhere in human physiology, including pregnancy, lactation, cyclical hormonal shifts, and menopause. Each involves profound changes in immunity, metabolism, tissue remodelling and ageing. These are natural experiments happening inside the human body, yet they’ve often been treated as side topics rather than scientific opportunities.

That was the moment during the event when the conversation shifted for me. The call to action is not only about addressing inequality in healthcare, although that remains essential. It’s also about curiosity, about recognising that by overlooking women’s biology, we may also be overlooking discoveries that could reshape our understanding of human health more broadly.

For those of us working across the life science ecosystem, including the One Nucleus community, this feels like an opportunity we shouldn’t ignore. We are the people who influence what gets explored next in research. The questions we ask, the research we fund, the companies we build and the collaborations we choose all shape where discovery happens.

So perhaps the challenge is simply to look again, to revisit the biology that has long been considered niche, and to see women’s health conditions not only as clinical challenges but as potential gateways into new science.

The loss isn’t only the women whose conditions remain under‑researched; it’s the discoveries we may be missing. The life sciences community rarely overlooks genuine scientific opportunity and it would be a real shame if this were the exception.